MedTrace Logo

Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury

NCT02001363 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2016-02-05

No results posted yet for this study

Summary

The investigators planned to research the cardioprotective effects of intravenous liraglutide on reperfusion injury.

Conditions

  • Acute Myocardial Infarction

Interventions

DRUG

liraglutide (Novo Nordisk, Bagsværd, Denmark)

once-daily subcutaneous liraglutide 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide 1.2 mg for 2 days ,once-daily subcutaneous liraglutide 1.8 mg for 3 days

DRUG

liraglutide placebo (Novo Nordisk)

once-daily subcutaneous liraglutide placebo 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide placebo 1.2 mg for 2 days ,once-daily subcutaneous liraglutide placebo 1.8 mg for 3 days

Sponsors & Collaborators

  • Chen Wei Ren, MD

    lead OTHER

Principal Investigators

  • Yun Dai Chen, M.D. · World Health Organization

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02001363 on ClinicalTrials.gov